{
    "organizations": [],
    "uuid": "96b01cfeef89c8cd6fea1c6414324bc2b2781b89",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/27/globe-newswire-zogenix-to-release-fourth-quarter-and-full-year-2017-financial-results-and-host-conference-call-and-webcast-on-march-6.html",
    "ord_in_thread": 0,
    "title": "Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call and Webcast on March 6",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "EMERYVILLE, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2017, after the market close, and will host a corporate update conference call and webcast on Tuesday, March 6, 2018, at 4:30 PM Eastern Time.\nConference Call Details Tuesday, March 6th @ 4:30 PM Eastern Time/1:30 PM Pacific Time Toll Free: 800-239-9838 International: 323-794-2551 Conference ID: 5092266 Webcast: http://public.viavid.com/index.php?id=128365 Replays, available through March 20: Domestic: 844-512-2921 International: 412-317-6671 Replay PIN: 5092266 About Zogenix\nZogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.\nFor more information, visit www.zogenix.com .\nCONTACT:\nInvestors: Andrew McDonald\nFounding Partner, LifeSci Advisors LLC\n646-597-6987 | Andrew@lifesciadvisors.com\nSource:Zogenix, Inc.",
    "published": "2018-02-27T16:00:00.000+02:00",
    "crawled": "2018-02-27T17:30:27.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "emeryville",
        "globe",
        "newswire",
        "zogenix",
        "nasdaq",
        "zgnx",
        "pharmaceutical",
        "company",
        "developing",
        "therapy",
        "treatment",
        "rare",
        "central",
        "nervous",
        "system",
        "cns",
        "disorder",
        "today",
        "announced",
        "report",
        "financial",
        "result",
        "fourth",
        "quarter",
        "ended",
        "december",
        "market",
        "close",
        "host",
        "corporate",
        "update",
        "conference",
        "call",
        "webcast",
        "tuesday",
        "march",
        "pm",
        "eastern",
        "time",
        "conference",
        "call",
        "detail",
        "tuesday",
        "march",
        "6th",
        "pm",
        "eastern",
        "pm",
        "pacific",
        "time",
        "toll",
        "free",
        "international",
        "conference",
        "id",
        "webcast",
        "http",
        "replay",
        "available",
        "march",
        "domestic",
        "international",
        "replay",
        "pin",
        "zogenix",
        "zogenix",
        "nasdaq",
        "zgnx",
        "pharmaceutical",
        "company",
        "committed",
        "developing",
        "commercializing",
        "cns",
        "therapy",
        "address",
        "specific",
        "clinical",
        "need",
        "people",
        "living",
        "orphan",
        "cns",
        "disorder",
        "need",
        "innovative",
        "treatment",
        "alternative",
        "improve",
        "daily",
        "functioning",
        "information",
        "visit",
        "contact",
        "investor",
        "andrew",
        "mcdonald",
        "founding",
        "partner",
        "lifesci",
        "advisor",
        "llc",
        "andrew",
        "source",
        "zogenix",
        "inc"
    ]
}